scholarly journals Capgras syndrome in substance-induced psychosis

2018 ◽  
Vol 10 (2) ◽  
pp. 38-39
Author(s):  
Bharat R. Sampathi ◽  
Anna Sofine ◽  
John Alvarez ◽  
Robert Bota
Keyword(s):  
Fatty Acids ◽  
Substance Use ◽  
Case Report ◽  
Family Member ◽  
Delusional Disorder ◽  
Psychiatric History ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Capgras Syndrome ◽  
Oxidative Effects

Capgras Syndrome is a subcategory of delusional disorder. People affected by this syndrome believe that a close associate such as a friend or family member has been replaced by an identical imposter. This case report describes a 23-year-old woman with no prior psychiatric history, whom developed Capgras syndrome, via folie a deux, in the setting of poly-substance use. In this patient, a combination of Aripiprazole 10 mg daily and Escitalopram 10 mg daily were effective in resolving symptoms. Clonazepam was utilized for anxiety and Omega-3 fatty acids 1 g for anti-oxidative effects. Further studies are needed to investigate the effects of a variety of causes and treatments for Capgras Syndrome.

scholarly journals Capgras syndrome in substance-induced psychosis

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
Bharat R. Sampathi ◽  
Anna Sofine ◽  
John Alvarez ◽  
Robert G. Bota
Keyword(s):  
Fatty Acids ◽  
Substance Use ◽  
Case Report ◽  
Family Member ◽  
Delusional Disorder ◽  
Psychiatric History ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Capgras Syndrome ◽  
Oxidative Effects

Capgras Syndrome is a subcategory of delusional disorder. People affected by this syndrome believe that a close associate such as a friend or family member has been replaced by an identical imposter. This case report describes a 23-year-old woman with no prior psychiatric history, whom developed Capgras syndrome, via folie a deux, in the setting of poly-substance use. In this patient, a combination of Aripiprazole 10 mg daily and Escitalopram 10 mg daily were effective in resolving symptoms. Clonazepam was utilized for anxiety and Omega-3 fatty acids 1 g for anti-oxidative effects. Further studies are needed to investigate the effects of a variety of causes and treatments for Capgras Syndrome.

scholarly journals Refractory Cutaneous IgA Vasculitis Treated with Omega-3 Fatty Acids

2016 ◽  
Vol 8 (3) ◽  
pp. 333-340 ◽  
Author(s):  
Maria A. Barnadas ◽  
Montserrat M. Díaz Encarnación
Keyword(s):  
Fatty Acids ◽  
Mycophenolate Mofetil ◽  
Case Report ◽  
Docosahexaenoic Acid ◽  
Therapeutic Strategies ◽  
Iga Vasculitis ◽  
Benzathine Penicillin ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
History Of

Background: Omega-3 fatty acids (O3FA) have been used to treat IgA nephropathy (IgAN) but not cutaneous IgA vasculitis (IgAV). Case Report: A 47-year-old female was referred for cutaneous vasculitis. She had a 24-year history of flares of palpable purpura, arthralgia associated with hematuria, and proteinuria. We diagnosed cutaneous IgAV associated with IgAN. We administered prednisone at doses ranging from 10 to 45 mg/day to control the flares. To reduce prednisone exposure, different therapeutic strategies (colchicine, diphenhydramine, hydroxyzine, azathioprine, benzathine penicillin, and mycophenolate mofetil) were applied without success. After 11 years, therapy with O3FA capsules containing 460 mg eicosapentaenoic acid and 380 mg of docosahexaenoic acid t.i.d. was introduced, allowing the prednisone to be stopped 2 years later. When the dose of O3FA was decreased to 1 capsule on alternate days, the cutaneous flares reappeared, but they were again controlled when the patient took 1 O3FA capsule daily. Conclusions: O3FA can be useful to control cutaneous IgAV.

Intravenous application of omega-3 fatty acids in a patient with active spondylarthropathy—a case report

2005 ◽  
Vol 25 (4) ◽  
pp. 577-578 ◽  
Author(s):  
Christian Fassl ◽  
Judith Sautner ◽  
Bernhard Rintelen ◽  
Burkhard F. Leeb
Keyword(s):  
Fatty Acids ◽  
Case Report ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Intravenous Application

scholarly journals The Use of Omega-3 Fatty Acids as an Alternative Treatment for Attention Deficit Hyperactivity Disorder in Children

2015 ◽  
Vol 22 (2) ◽  
pp. 47-52
Author(s):  
Samra M. Suliman
Keyword(s):  
Fatty Acids ◽  
Attention Deficit Hyperactivity Disorder ◽  
Case Report ◽  
Attention Deficit ◽  
Alternative Treatment ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Hyperactivity Disorder ◽  
Psychopharmacological Agents

This case report studies the effi cacy of omega-3 fatty acids as an alternative to using psychopharmacological agents for treating patients with Attention-Deficit Hyperactivity Disorder. While this study may not end the controversy concerning the eff ectiveness of omega-3, it does establish a very solid case for using omega-3 fatty acids as an augmenting agent along with a lower than recommended minimum starting stimulant dose.  

Fish oil plus wheat germ oil have no prominent effect on homocysteine levels and nutritional indices in hemodialysis patients

2019 ◽  
pp. 1-7
Author(s):  
Hadeer Zakaria ◽  
Tarek M. Mostafa ◽  
Gamal A. El-Azab ◽  
Nagy AH Sayed-Ahmed
Keyword(s):  
Fatty Acids ◽  
Vitamin E ◽  
Fish Oil ◽  
Wheat Germ ◽  
Hemodialysis Patients ◽  
Nutritional Indices ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Wheat Germ Oil ◽  
Serum Homocysteine

Abstract. Background: Elevated homocysteine levels and malnutrition are frequently detected in hemodialysis patients and are believed to exacerbate cardiovascular comorbidities. Omega-3 fatty acids have been postulated to lower homocysteine levels by up-regulating metabolic enzymes and improving substrate availability for homocysteine degradation. Additionally, it has been suggested that prevention of folate depletion by vitamin E consumption decreases homocysteine levels. However, data on the effect of omega-3 fatty acids and/or vitamin E on homocysteine levels and nutritional status have been inconclusive. Therefore, this study was planned to examine the effect of combined supplementation of fish oil, as a source of omega-3 fatty acids, with wheat germ oil, as a source of vitamin E, on homocysteine and nutritional indices in hemodialysis patients. Methods: This study was a randomized, double-blind, placebo-controlled trial. Forty-six hemodialysis patients were randomly assigned to two equally-sized groups; a supplemented group who received 3000 mg/day of fish oil [1053 mg omega-3 fatty acids] plus 300 mg/day of wheat germ oil [0.765 mg vitamin E], and a matched placebo group who received placebo capsules for 4 months. Serum homocysteine and different nutritional indices were measured before and after the intervention. Results: Twenty patients in each group completed the study. At the end of the study, there were no significant changes in homocysteine levels and in the nutritional indices neither in the supplemented nor in the placebo-control groups (p > 0.05). Conclusions: Fish oil and wheat germ oil combination did not produce significant effects on serum homocysteine levels and nutritional indices of hemodialysis patients.

Sign in / Sign up

Export Citation Format

Share Document